Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
japanese cedar pollen extract
- Development stage
- Phase 4
- Lead developer
- Torii Pharmaceutical
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
TO-194SL, marketed under the brand name CEDARTOLEN, is a sublingual immunotherapy (SLIT) liquid formulation developed by Torii Pharmaceutical for the treatment of Japanese cedar pollinosis. It contains a standardized extract of Japanese cedar (*Cryptomeria japonica*) pollen allergens, primarily Cry j 1 and Cry j 2. The drug is administered sublingually on a daily basis to induce immunological tolerance, thereby reducing the allergic response and alleviating symptoms of seasonal allergic rhinitis caused by Japanese cedar pollen. Approved in Japan in 2014, it was the first SLIT product available for this indication. Long-term studies, including Phase IV evaluations, have assessed its efficacy over multi-year treatment periods and the persistence of its therapeutic effects after treatment cessation.
- Brand names
- CEDARTOLEN
- Other names
- Japanese cedar pollen sublingual drop
02
Targets
Immunoglobulin E specific for Cryptomeria japonica allergens 1 and 2 (Cry j 1/2-specific IgE)T-cell receptor on Cry j 1/Cry j 2-specific CD4+ T cellMac-1/PAR-2 (Integrin alpha-M beta-2 and Protease-activated receptor 2)Cry j 2
Beyond the preview
Go deeper on japanese cedar pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on japanese cedar pollen extract.